What if the cure to antibiotic resistance isn’t man-made—but viral? The Phage Therapy unlocks the hidden world of bacteriophages, revealing breakthroughs that could transform medicine. With fresh insights every two days, it feeds your curiosity, challenges what you think you know, and leaves you asking: why haven’t I heard about this before? Enter the world most people overlook—before it changes everything.
Recent News 44 : A New Tool Not To Be Missed To Explore Phages
Get link
Facebook
X
Pinterest
Email
Other Apps
-
Merck and Sigma-Aldrich have released recently a new product, the Anti-fd Bacteriophage antibody produced in rabbit.
Property
Details :
Biological Source
Rabbit
Quality Level
200
Conjugate
Unconjugated
Antibody Form
IgG fraction of antiserum
Antibody Product Type
Primary antibodies
Clone
Polyclonal
Form
Buffered aqueous solution
Packaging
Antibody small pack of 25 μL
Technique(s)
Indirect ELISA: 1:1,000 using 5 × 10¹⁰ phage/ml
Shipped In
Dry ice
Storage Temperature
−20°C
Target Post-Translational Modification
Unmodified
ELISA Anti-FD Bacteriophage antibody produced in Rabbit (Cat. No. B7786), followed by 1:1,000 Anti-Rabbit IgG (whole molecule)-Peroxidase antibody produced in Goat (Cat. No. A0545), was serially diluted to detect FD Bacteriophage by indirect ELISA.
Specificity
The antibody binds specifically to phage coat proteins of fd phage or M13 phage and thus may act as a capture antibody when coated directly on multiwell plates or as a primary detection antibody for specifically captured fd or M13 phage. The antibody may be useful in rapidly sorting large phage display libraries (antibody, peptide, etc.) with the expressed proteins fused to either the gene III or to the gene VIII protein of the filamentous phage. The antibody may be used as a reagent in "phage ELISA" offering sensitive and specific activity for detection of recombinant phages.
Immunogen
fd bacteriophage
Application
Anti-fd Bacteriophage antibody produced in rabbit may be used in ELISA at a dilution of 1:1000. It was used to in antiphage immunohistochemistry.
B7786 Rabbit Anti-fd Bactieriophage may be used to sort phage display libraries (antibody, peptide, etc.) with expressed proteins fused to either the gene III or gene VIII protein of filamentous bacteriophage. The product may also be used in "phage ELISA" offering specific activity for detection of recombinant bacteriophage. It will also function as a capture antibody when coated directly on microwell plates or as primary detection antibody for specifically captured fd or M13 bacteriophage.
Physical form
Solution supplied in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide
Preparation Note
Anti-fd Bacteriophage is developed in rabbit using repeated injections of fd bacteriophage as the immunogen. Whole antiserum is fractionated and then further purified by ion-exchange chromatography to provide the IgG fraction of antiserum which is essentially free of other rabbit serum proteins.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Post-War Stagnation and Phage Therapy’s Marginalization in the West (1945–1980s) The period following World War II marked a decisive turning point in the trajectory of phage therapy in Western medicine. Despite the promising results bacteriophages had demonstrated prior to the war as potential antibacterial agents, the decades after 1945 saw a dramatic decline in interest, funding, and scientific engagement with phage therapy in the United States and much of Western Europe. This marginalization can be attributed to a confluence of scientific, sociopolitical, and economic factors that reshaped the landscape of infectious disease treatment and research. Artistic View One of the key contributors to this decline was the overwhelming optimism surrounding the newly discovered class of antibiotics. The post-war pharmaceutical revolution brought forward a series of broad-spectrum antibiotics such as streptomycin, tetracycline, and chloramphenicol, which were viewed as miracle drugs capable o...
Bacteriophages: Ancient Predators and the Next Frontier in Medicine In the animated documentary The Deadliest Being on Planet Earth , the Kurzgesagt team delves into the world of bacteriophages—viruses that prey exclusively on bacteria. With vibrant visuals and precise narration, the video introduces viewers to an invisible ecosystem where microscopic hunters orchestrate life-and-death dramas that shape the biosphere. These entities, though virtually unknown to the general public, may soon become central to the future of medicine. At the heart of the video lies a paradox: bacteriophages (or "phages") are among the most abundant biological entities on Earth—outnumbering all other organisms combined—yet their therapeutic potential has been largely sidelined in the antibiotic era. The video outlines the historical trajectory of phage research, spotlighting Félix d’Hérelle’s early 20th-century work and the rise of phage therapy, only to show how it was later eclipsed by the dis...
Phage Therapy May Treat Drug Resistance in Patients With Cystic Fibrosis, Study Finds June 13, 2025 "Yale's university researchers find a new approach to combatting antimicrobial resistance. Antimicrobial resistance, in which germs like bacteria and fungi no longer respond to medicines, is a rising global threat. When antibiotics and other drugs become ineffective, infections can become difficult or impossible to treat, leading to an increase in the spread and severity of disease. In a new study, published in Nature Medicine , a team of researchers at the Center for Phage Biology and Therapy at Yale discovered a novel approach that may revolutionize the fight against antimicrobial resistance. Jon Koff, MD, with a patient Credit: Robert A. Lisak For the study, the research team investigated the use of phage therapy—the use of viruses, or phages, to target and kill bacteria—to help patients with cystic fibrosis, a disease in which antimicrobial resistance is a significant issue....
.png)
Comments
Post a Comment